{"groups":[{"description":"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)","id":"FG000","title":"Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"HAMA + post dosimetry"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This protocol is open to participants age 18 and above, of either gender and any race/ethnicity. The study is looking at the use of Y-90-DOTA-BC8 in conjunction with a standard reduced-intensity transplant regimen."}